Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 10:21 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 44 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Overactive Detrusor Clear all
Withdrawn Phase 2 Interventional

Botulinum-A Toxin Injection for Detrusor Hyperreflexia in Spinal Cord Injury: A Non-Surgical Approach.

NCT00262496
View directory record Official record
Conditions
Overactive Bladder, Urinary Incontinence
Interventions
Botox
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 25, 2015 · Synced Jul 21, 2026, 10:21 PM EDT
Completed Phase 3 Interventional Results available

Study of OnabotulinumtoxinA (BOTOX®) for Urinary Incontinence Due to Neurogenic Detrusor Overactivity in Pediatric Patients

NCT01852045
View directory record Official record
Conditions
Urinary Incontinence
Interventions
OnabotulinumtoxinA
Biological
Lead sponsor
Allergan
Industry
Eligibility
5 Years to 17 Years
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
14
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, California + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2019 · Synced Jul 21, 2026, 10:21 PM EDT
Completed Phase 4 Interventional Results available

Study of 2 Doses of Solifenacin Succinate in Female Subjects With Overactive Bladder.

NCT01093534
View directory record Official record
Conditions
Detrusor Overactivity, Overactive Bladder
Interventions
Placebo, solifenacin
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older · Female only
Enrollment
547 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
3
States / cities
New York, New York • West Reading, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 2, 2024 · Synced Jul 21, 2026, 10:21 PM EDT
Completed Phase 4 Interventional Results available

Minimizing Pain During Office Intradetrussor Botox Injection

NCT04270526
View directory record Official record
Conditions
Overactive Bladder, Overactive Detrusor, Overactive Bladder Syndrome, Overactivity; Behavior, Urge Incontinence
Interventions
Bicarbonate protocol, Standard protocol
Drug
Lead sponsor
Boston Urogynecology Associates
Other
Eligibility
18 Years and older · Female only
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 5, 2025 · Synced Jul 21, 2026, 10:21 PM EDT
Not yet recruiting Phase 4 Interventional

Optimal Intravesical Lidocaine Volume for Pain Relief During Office Intra-detrusor Onabotulinum Toxin a Injections

NCT06695585
View directory record Official record
Conditions
Overactive Bladder, Overactive Bladder Syndrome, Urinary Urgency, Urinary Frequency, Urge Incontinence, Neurogenic Bladder
Interventions
Lidocaine 2% without vessel constrictor
Drug
Lead sponsor
University of Louisville
Other
Eligibility
18 Years and older · Female only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Nov 18, 2024 · Synced Jul 21, 2026, 10:21 PM EDT
Terminated No phase listed Observational

Sensitivity of Extended Cultures in Diagnosing Urinary Tract Infections

NCT03080389
View directory record Official record
Conditions
Overactive Bladder, Overactive Detrusor, Urgency-Frequency Syndrome, UTI
Interventions
Extended Urine Culture
Procedure
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Weston, Florida
Source: ClinicalTrials.gov public record
Updated Sep 3, 2018 · Synced Jul 21, 2026, 10:21 PM EDT
Terminated Phase 2 Interventional Results available

A Two-week Open-label Pharmacodynamic and Pharmacokinetic Study of Multiple Doses of a Darifenacin Liquid Oral Suspension in Children (2 - 15 Years) With Neurogenic Detrusor Overactivity

NCT00712322
View directory record Official record
Conditions
Neurogenic Detrusor Overactivity
Interventions
Darifenacin
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
2 Years to 15 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
9
States / cities
San Diego, California • Boston, Massachusetts • Detroit, Michigan + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2022 · Synced Jul 21, 2026, 10:21 PM EDT
Completed Phase 3 Interventional Results available

A Study To Find Out How Fesoterodine Works In Children Aged 6 To 17 Years With Bladder Overactivity Caused By A Neurological Condition

NCT01557244
View directory record Official record
Conditions
Urinary Bladder, Neurogenic
Interventions
Fesoterodine PR 4 mg, Fesoterodine PR 8 mg, Oxybutynin, Fesoterodine PR, Fesoterodine BIC 2 mg, Fesoterodine BIC 4 mg
Drug
Lead sponsor
Pfizer
Industry
Eligibility
6 Years to 17 Years
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
18
States / cities
Tucson, Arizona • Orange, California • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2021 · Synced Jul 21, 2026, 10:21 PM EDT
Terminated Not applicable Interventional

Pulsed Electromagnetic Stimulation for Treatment of Overactive Bladder

NCT00805779
View directory record Official record
Conditions
Urinary Bladder, Overactive
Interventions
MagPro R30
Device
Lead sponsor
EMKinetics, Inc
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 7, 2011 · Synced Jul 21, 2026, 10:21 PM EDT
Completed Phase 4 Interventional

A Study of Effects of Fesoterodine in Men at High Risk for Overactive Bladder/Detrusor Overactivity Post Robotic-Assisted Lap. Prostatectomy

NCT01661166
View directory record Official record
Conditions
Prostate Adenocarcinoma
Interventions
Fesoterodine, Placebo oral tablet
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
30 Years to 90 Years · Male only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 27, 2020 · Synced Jul 21, 2026, 10:21 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

UNGF Assessment in Patients With Detrusor Overactivity Undergoing Sacral Neuromodulation

NCT01850706
View directory record Official record
Conditions
Detrusor Overactivity
Interventions
Not listed
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
1
States / cities
Manhasset, New York
Source: ClinicalTrials.gov public record
Updated Oct 25, 2016 · Synced Jul 21, 2026, 10:21 PM EDT
Recruiting Phase 2Phase 3 Interventional

Open-label, Long-term Safety, Efficacy, and Pharmacokinetics Study of Vibegron in Pediatric Subjects 2 Years to < 18 Years of Age With NDO and on CIC

NCT05491525
View directory record Official record
Conditions
Neurogenic Detrusor Overactivity
Interventions
Vibegron
Drug
Lead sponsor
Urovant Sciences GmbH
Industry
Eligibility
2 Years to 17 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
11
States / cities
Little Rock, Arkansas • Orange, California • Aurora, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Jul 21, 2026, 10:21 PM EDT
Recruiting Not applicable Interventional

Yoga for Treatment of Overactive Bladder in Pediatric Patients

NCT05895045
View directory record Official record
Conditions
Overactive Bladder, Overactive Bladder Syndrome, Overactive Detrusor
Interventions
Yoga
Behavioral
Lead sponsor
Duke University
Other
Eligibility
8 Years to 18 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Jul 21, 2026, 10:21 PM EDT
Recruiting Phase 1Phase 2 Interventional

Dose Escalation Study of EG110A, Administered by Intradetrusor Injections to Adults With Neurogenic Detrusor Overactivity-related Incontinence Following Spinal Cord Injury Who Regularly Perform Clean Intermittent Catheterization

NCT06596291
View directory record Official record
Conditions
Neurogenic Detrusor Overactivity, Spinal Cord Injuries
Interventions
EG110A
Drug
Lead sponsor
Cyllene Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
4
States / cities
Downey, California • Ann Arbor, Michigan • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Jul 21, 2026, 10:21 PM EDT
Completed Phase 4 Interventional Results available

Safety and Efficacy Study of Transdermal Oxybutynin to Treat Overactive Bladder With a Neurological Condition

NCT00224016
View directory record Official record
Conditions
Detrusor Hyperreflexia
Interventions
Oxybutynin
Drug
Lead sponsor
Watson Pharmaceuticals
Industry
Eligibility
6 Years to 15 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
23
States / cities
Little Rock, Arkansas • Orange County, California • San Diego, California + 20 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2012 · Synced Jul 21, 2026, 10:21 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Neurogenic Detrusor Overactivity (NDO) in Non-Catheterizing Patients With Multiple Sclerosis (MS)

NCT01600716
View directory record Official record
Conditions
Urinary Incontinence, Multiple Sclerosis, Neurogenic Bladder
Interventions
OnabotulinumtoxinA, Placebo (Normal Saline)
Biological · Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Mountlake Terrace, Washington
Source: ClinicalTrials.gov public record
Updated Apr 29, 2019 · Synced Jul 21, 2026, 10:21 PM EDT
Completed Phase 4 Interventional Results available

A Study Evaluating Oxybutynin in Patients With Neurogenic Overactive Bladder Associated With a Neurological Condition

NCT00224029
View directory record Official record
Conditions
Detrusor Hyperreflexia
Interventions
Oxybutynin transdermal system
Drug
Lead sponsor
Watson Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
6
States / cities
Atlanta, Georgia • The Bronx, New York • Chapel Hill, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2010 · Synced Jul 21, 2026, 10:21 PM EDT
Terminated Phase 3 Interventional Results available

Over Active Bladder Instillation Study - Botox

NCT00667095
View directory record Official record
Conditions
Overactive Bladder, Urinary Urge Incontinence, Urinary Incontinence, Detrusor Hyperreflexia, Urge Incontinence
Interventions
Botox Instillation, DMSO Instillation
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 10, 2014 · Synced Jul 21, 2026, 10:21 PM EDT
Completed No phase listed Observational Results available

Central Nervous System Changes Following OnabotulinumtoxinA Injection in the Bladder

NCT03033355
View directory record Official record
Conditions
Multiple Sclerosis, Lower Urinary Tract Symptoms, Neurogenic Bladder, Detrusor, Overactive, Urge Incontinence
Interventions
Intra-detrusor injection of Onabotulinumtoxin-A
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 4, 2025 · Synced Jul 21, 2026, 10:21 PM EDT
Terminated No phase listed Observational

A Pilot Trial in a Sleep Laboratory Setting to Observe Night Time Bladder Function of Subjects With Overactive Bladder (OAB)

NCT01099345
View directory record Official record
Conditions
Bladder Function
Interventions
cystometry (CMG), polysomnography (PSG)
Procedure
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 3, 2014 · Synced Jul 21, 2026, 10:21 PM EDT
Recruiting No phase listed Observational

Feasibility of Triggered Sacral Neuromodulation for Neurogenic Bladder

NCT05141487
View directory record Official record
Conditions
Urinary Incontinence, Urinary Bladder, Neurogenic
Interventions
UroMonitor, ASCU
Device
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Jul 21, 2026, 10:21 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Botulin-A Toxin Instillations and Overactive Bladder

NCT00583219
View directory record Official record
Conditions
Overactive Bladder, Detrusor Instability, Detrusor Hyperreflexia
Interventions
Botulinum-A toxin, Dimethyl sulfoxide (DMSO)
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 20, 2014 · Synced Jul 21, 2026, 10:21 PM EDT
Completed Not applicable Interventional Results available

Optimization of OnabotulinumtoxinA (BTX-A) Injection for the Treatment of Neurogenic Lower Urinary Tract Dysfunction

NCT06059066
View directory record Official record
Conditions
Neurogenic Bladder, Lower Urinary Tract Symptoms, Overactive Bladder, Neuro: Neurogenic Bladder, Neurogenic Detrusor Overactivity
Interventions
Standard number of injection sites, Reduced number of injection sites
Procedure
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 8, 2025 · Synced Jul 21, 2026, 10:21 PM EDT
Recruiting No phase listed Observational

Noninvasive Ultrasound Assessment of Detrusor Dysfunction

NCT05652023
View directory record Official record
Conditions
Bladder Dysfunction, Overactive Bladder, BPH With Urinary Obstruction
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 90 Years
Enrollment
2,023 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Jul 21, 2026, 10:21 PM EDT